Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135763 | 0.90 | HRH3 (0.59) | HRH3KCNH2USP30 | |
| SCHEMBL4129121 | 0.85 | HRH3 (0.39) | HRH3KCNH2USP30CYP1A2CYP11B1 | |
| SCHEMBL4142343 | 0.85 | HRH3 (0.40) | HRH3KCNH2USP30CYP1A2CYP11B1 | |
| SCHEMBL4141100 | 0.84 | HRH3 (0.38) | HRH3KCNH2CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL4135773 | 0.83 | CYP11B1 (0.37) | HRH3KCNH2PDK1PDK2PDK3 | |
| SCHEMBL4132406 | 0.83 | MCHR1 (0.37) | HRH3KCNH2MCHR1CYP1A2CYP11B1 | |
| SCHEMBL4133559 | 0.83 | HRH3 (0.47) | HRH3USP30PDK1PDK2PDK3 | |
| SCHEMBL4136097 | 0.81 | TMEM97 (0.46) | HRH3MCHR1CYP11B1CYP11B2DRD3 | |
| SCHEMBL4135535 | 0.81 | ASIC3 (0.35) | HRH3KCNH2MCHR1CYP1A2CYP11B1 | |
| SCHEMBL4130668 | 0.80 | ASIC3 (0.46) | HRH3KCNH2MCHR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 657/4885USP30 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.